A5046896524- Heart Failure Treatment and Management
- Mesenchymal stem cell research
- Cardiovascular Function and Risk Factors
- Mechanical Circulatory Support Devices
- Cardiac Fibrosis and Remodeling
- Cardiac Imaging and Diagnostics
- Cardiac pacing and defibrillation studies
- Tissue Engineering and Regenerative Medicine
- GDF15 and Related Biomarkers
- Acute Myocardial Infarction Research
- Coronary Interventions and Diagnostics
- Pain Management and Treatment
- Hemodynamic Monitoring and Therapy
- Cardiac Structural Anomalies and Repair
- Blood Pressure and Hypertension Studies
- Cardiac Ischemia and Reperfusion
- Signaling Pathways in Disease
- Pulmonary Hypertension Research and Treatments
- Electrospun Nanofibers in Biomedical Applications
- Liver Disease Diagnosis and Treatment
- Cardiac and Coronary Surgery Techniques
- Healthcare Policy and Management
- Health Systems, Economic Evaluations, Quality of Life
- Liver Disease and Transplantation
- Infective Endocarditis Diagnosis and Management
Northwest Hospital
2018-2024
Pacific Clinics
2020-2024
Noordwest Ziekenhuisgroep
2018-2024
Haga Hospital
2023
Radiance Technologies (United States)
2023
Ralph H. Johnson VA Medical Center
2023
Medical University of South Carolina
2023
Medisch Centrum Alkmaar
2019
Leiden University Medical Center
2008-2018
Leiden University
2008-2014
Previous studies have suggested that bone marrow cell injection may improve myocardial perfusion and left ventricular (LV) function in patients with chronic ischemia.To investigate the effect of intramyocardial on LV ischemia.Randomized, double-blind, placebo-controlled trial at a Netherlands university hospital, May 1, 2005-March 3, 2008 (6-month follow-up ended September 2008) 50 ischemia (mean age [SD], 64 [8] years; 43 men).severe angina pectoris despite optimal medical therapy ischemia....
Abstract Aims Despite clear guideline recommendations for initiating four drug classes in all patients with heart failure (HF) reduced ejection fraction (HFrEF) and the availability of rapid titration schemes, information on real‐world implementation lags behind. Closely following 2021 ESC HF guidelines 2023 focused update, TITRATE‐HF study started to prospectively investigate use, sequencing, guideline‐directed medical therapy (GDMT) patients, including identification barriers. Methods...
In experimental studies, mesenchymal stem cell (MSC) transplantation in acute myocardial infarction (AMI) models has been associated with enhanced neovascularization and myogenesis. Clinical data however, are scarce. Therefore, the present study evaluates safety feasibility of intramyocardial MSC injection nine patients, shortly after AMI during short-term 5-year follow-up. Periprocedural analysis demonstrated one transient ischemic attack. No other adverse events related to treatment were...
HFrEF is a heterogenous condition with high mortality. We used serial assessments of 4210 circulating proteins to identify distinct novel protein-based subphenotypes and investigate underlying dynamic biological mechanisms. Herewith we aimed gain pathophysiological insights fuel opportunities for personalised treatment.In 382 patients, performed trimonthly blood sampling during median follow-up 2.1 [IQR:1.1-2.6] years. selected all baseline samples two closest the primary endpoint (PEP;...
In patients with chronic heart failure (HF), the MONITOR-HF trial demonstrated efficacy of pulmonary artery (PA)-guided HF therapy over standard care in improving quality life and reducing hospitalizations mean PA pressure. This study aimed to evaluate consistency these benefits relation clinically relevant subgroups.
Intramyocardial bone marrow cell injection is associated with improvements in myocardial perfusion and anginal symptoms patients refractory angina pectoris. This study evaluates the effect of repeated intramyocardial residual or recurrent ischemia.Twenty-three (17 men; 69±9 years) who had improved after first but ischemia on single-photon emission computed tomographic imaging were included. Patients again received 100×10(6) autologous mononuclear cells, 4.6±2.5 years their injection. No...
Background Remodeling biomarkers carry high potential for predicting adverse events in chronic heart failure ( CHF ) patients. However, temporal patterns during the course of , and especially trajectory before an event, are unknown. We studied prognostic value 14 cardiac remodeling biomarker candidates stable patients with from Bio-SHiFT (Serial Biomarker Measurements New Echocardiographic Techniques Chronic Heart Failure Patients Result Tailored Prediction Prognosis) study. Methods Results...
Assessing haemodynamic congestion based on filling pressures instead of clinical can be a way to further improve quality life (QoL) and outcome by intervening before symptoms or weight gain occur in heart failure (HF) patients. The efficacy remote monitoring pulmonary artery (PA) (CardioMEMS; Abbott Inc., Atlanta, GA, USA) has been demonstrated the USA. Currently, PA sensor is not reimbursed European Union as its benefit when applied addition standard HF care unknown Western countries,...
Abstract The aim of our observational study was to derive a small set out 92 repeatedly measured biomarkers with optimal predictive capacity for adverse clinical events in heart failure, which could be used dynamic, individual risk assessment practice. In 250 chronic HFrEF (CHF) patients, we collected trimonthly blood samples during median 2.2 years. We selected 537 repeated measurement the Cardiovascular Panel III (Olink Proteomics AB). applied Least Absolute Shrinkage and Selection...
Abstract Purpose Multiple hormonal and metabolic alterations occur in chronic heart failure (CHF), but their proper monitoring during clinically silent progression of CHF remains challenging. Hence, our objective was to explore whether temporal patterns six emerging cardiometabolic biomarkers predict future adverse clinical events stable patients with CHF. Methods In 263 CHF, we determined the risk a composite end point hospitalization, cardiac death, left ventricular assist device...
BackgroundOur aim was to explore potential use of temporal profiles seven emerging cardio-renal and two pulmonary candidate biomarkers for predicting future adverse clinical outcome in stable patients with chronic heart failure (CHF).MethodsIn 263 CHF patients, we determined the risk a composite endpoint HF-hospitalization, cardiac death, LVAD-placement transplantation relation repeatedly assessed (567 samples total) blood biomarker levels, slopes their trajectories (i.e., rate change per...
Abstract Aims Evidence on the association of macrophage‐ and neutrophil‐related blood biomarkers with clinical outcome in heart failure patients is limited, and, exception C‐reactive protein, no data exist their temporal evolution. We aimed to investigate whether patterns these are related stable chronic (CHF). Methods Results In 263 CHF, we performed serial plasma measurements scavenger receptor cysteine‐rich type 1 protein M130 (CD163), tartrate‐resistant acid phosphatase 5 (TRAP),...
We recently demonstrated in a randomized, double-blind, placebo-controlled trial that intramyocardial bone marrow cell (BMC) injection is associated with improvements myocardial perfusion and anginal symptoms chronic ischemia patients. In the present study results of crossover phase this trial, which patients previously treated placebo received autologous BMC injections are reported. This allows unique intra-patient comparison on effect versus elimination patient-related confounding...
Cardiovascular inflammation and vascular endothelial dysfunction are involved in chronic heart failure (CHF), cellular adhesion molecules considered to play a key role these mechanisms. We evaluated temporal patterns of 12 blood biomarkers cell patients with CHF. In 263 ambulant patients, serial, tri-monthly samples were collected during median follow-up 2.2 (1.4–2.5) years. The primary endpoint (PE) was composite cardiovascular mortality, HF hospitalization, transplantation implantation...
Current heart failure (HF) guidelines recommend to prescribe four drug classes in patients with HF reduced ejection fraction (HFrEF). A clear challenge exists adequately implement guideline-directed medical therapy (GDMT) regarding the sequencing of drugs and timely reaching target dose. It is largely unknown how paradigm shift from a serial sequential approach for early parallel application will be executed daily clinical practice, as well reason clinicians may not adhere new guidelines. We...
<h3>Objective:</h3> To evaluate the effect of bone marrow cell injection on global strain and left ventricular (LV) dyssynchrony. <h3>Methods:</h3> In 14 patients with severe postinfarction heart failure, 93 (14)×106 autologous cells were percutaneously injected in infarction border zone. LV ejection fraction (LVEF), dyssynchrony echocardiographic assessed at baseline 3 months a non-randomised control group 10 history who developed failure treated medically. <h3>Results:</h3> No...
The present substudy of a recently published randomized trial aimed to investigate the effect intramyocardial bone marrow cell injection on diastolic function in patients with chronic myocardial ischemia.In total 50 patients, was evaluated before and 3 months after using standard echocardiography strain analysis. In addition, MRI-derived transmitral flow measurements were obtained subset 36 patients. Left ventricular ejection fraction increased from 50±5% 54±7% group, which significant...
Abstract Aims Heart failure (HF), a global pandemic affecting millions of individuals, calls for adequate predictive guidance improved therapy. Congestion, key factor in HF‐related hospitalizations, further underscores the need timely interventions. Proactive monitoring intracardiac pressures, guided by pulmonary artery (PA) pressure, offers opportunities efficient early‐stage intervention, since haemodynamic congestion precedes clinical symptoms. Methods The BioMEMS study, substudy...
Data regarding angiographic characteristics, clinical profile, and inhospital outcomes of patients with coronavirus disease 2019 (COVID-19) referred for coronary angiography (CAG) are scarce. This is an observational study analyzing confirmed COVID-19 CAG from 10 European centers. We included 57 (mean age: 66 ± 15 years, 82% male) , whom 18% had previous myocardial infarction (MI) 29% renal insufficiency chronic pulmonary disease. ST-segment elevation (STEMI) was the most frequent indication...
Abstract Background It is uncertain that chronic heart failure (CHF) patients are susceptible to renal tubular damage with of worsening function (WRF) preceding clinical outcomes. Hypothesis Changes in biomarkers stronger predictors subsequent events than changes creatinine (Cr), and both have different determinants. Methods During 2.2 years, we repeatedly simultaneously collected a median 9 blood 8 urine samples per patient 263 CHF patients. We determined the slopes (rates change) biomarker...